Research
Hormonal
Semaglutide 2.4 mg weekly produces a sustained, slowly decaying weight loss effect in adults with obesity, with an estimated 14.9% reduction in body weight over 68 weeks compared to placebo.
Take 2.4 mg of semaglutide once weekly as part of a lifestyle intervention. Expect significant weight loss (around 15% over 68 weeks) compared to placebo. Adherence is key, as discontinuation reduces effectiveness.
StrongSupportsHIGH confidence
When applied to STEP 1, they suggest a sustained, slowly decaying weight loss effect of semaglutide treatment.
Why this rating
Based on a large, randomized, double-blind, placebo-controlled trial (STEP 1) with 1961 participants.
Source
Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial
Jack Bowden et al. · Statistics in Medicine · 2025
DOI 10.1002/sim.70076
rct · n=1961Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →